Literature DB >> 31488385

Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis.

Robert H P de Meel1, Martijn R Tannemaat2, Jan J G M Verschuuren3.   

Abstract

The distribution of muscle weakness in myasthenia gravis (MG) patients with acetylcholine receptor (AChR) antibodies is highly variable. As muscle groups respond differently to therapeutic interventions, it is important to acknowledge this variability. We analysed the distribution of muscle weakness in 225 AChR MG patients over time. On the basis of combinations of muscle weakness, seven phenotypes were defined: 'ocular' (O), 'bulbar' (B), 'neck/limbs/respiratory' (NLR), or a combination (O+B, O+NLR, B+NLR and O+B+NLR). MG remained restricted to ocular weakness in 5%, whereas 7% never had ocular weakness. At last follow-up, ocular or bulbar weakness had resolved more frequently than NLR weakness (40%, 38% and 25%; p = 0.003, respectively). Patients with O, B or OB phenotype at baseline had a higher age at onset and were more frequently male than patients with NLR, ONLR, BNLR or OBNLR phenotype (52.7 ± 17.5 vs. 44.0 ± 18.9; p = 0.007 and 64% vs. 37%; p = 0.002, respectively). MG patients have heterogeneous distributions of muscle weakness and frequently shift between phenotypes. The phenotypic variations found in AChR MG suggest that also other factors aside from the AChR antibody mediated immune response are of importance in determining the disease expression in MG.
Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune disease; Fluctuations; Myasthenia gravis; Neuromuscular disease; Phenotype; Subtype

Mesh:

Substances:

Year:  2019        PMID: 31488385     DOI: 10.1016/j.nmd.2019.07.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  3 in total

1.  Association of Cardiac Autonomic Responses with Clinical Outcomes of Myasthenia Gravis: Short-Term Analysis of the Heart-Rate and Blood Pressure Variability.

Authors:  Monika Zawadka-Kunikowska; Łukasz Rzepiński; Małgorzata Tafil-Klawe; Jacek J Klawe; Paweł Zalewski; Joanna Słomko
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

2.  MiR-522-3p inhibits proliferation and activation by regulating the expression of SLC31A1 in T cells.

Authors:  Hengxiao Lu; Hao Wang; Peidao Sun; Jiang Wang; Shuhai Li; Tongzhen Xu
Journal:  Cytotechnology       Date:  2021-05-07       Impact factor: 2.040

Review 3.  Possible implications of dysregulated nicotinic acetylcholine receptor diffusion and nanocluster formation in myasthenia gravis.

Authors:  Francisco J Barrantes
Journal:  Neural Regen Res       Date:  2021-02       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.